Document details

Preclinical anticancer effectiveness of a fraction from Casearia sylvestris and its component Casearin X: in vivo and ex vivo methods and microscopy examinations


Description

Made available in DSpace on 2018-11-27T16:55:43Z (GMT). No. of bitstreams: 0 Previous issue date: 2016-06-20

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Ethnopharmacological relevance: Casearia sylvestris (Salicaceae) is found in South America and presents antiulcerogenic, cytotoxic, antimicrobial, anti-inflammatory and antihypertensive activities. Aim of the study: To assess the in vivo and ex vivo antitumor action of a fraction with casearins (FC) and its main component- Casearin X-isolated from C sylvestris leaves. Materials and methods: Firstly, Sarcoma 180 bearing Swiss mice were treated with FC and Cas X for 7 days. Secondly, BALB/c nude animals received hollow fibers with colon carcinoma (HCT-116) or glioblastoma (SF-295) cells and were treated with FC for 4 days. On 5th day, proliferation was determined by MIT assay. Results: FC 10 and 25 mg/kg/day i.p. and 50 mg/kg/day oral and Cas X 25 mg/kg/day i.p. and 50 mg/kg/ day oral revealed tumor growth inhibition rates of 35.8, 86.2, 53.7, 90.0 and 65.5% and such tumors demonstrated rare mitoses and coagulation necrosis areas. Similarly, FC reduced multiplying of HCT-116 and SF-295 cells when evaluated by the Hollow Fiber Assay (2.5 and 5 mg/kg/day i.p. and 25 and 50 mg/ kg/day oral), with cell growth inhibition rates ranging from 33.3 to 67.4% (p < 0.05). Flow cytometry experiments revealed that FC reduced membrane integrity and induced DNA fragmentation and mitochondrial depolarization (p < 0.05). Conclusions: FC and Cas X were efficient antitumor substances against murine and human cancer cells and caused reversible morphological changes in liver, kidneys and spleens, emphasizing clerodane diterpenes as an emerging class of anticancer molecules. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

Univ Fed Piaui, Dept Physiol & Biophys, Expt Cancerol Lab, Teresina, Brazil

Univ Fed Piaui, Postgrad Program Pharmaceut Sci, Teresina, Brazil

Univ Fed Piaui, Postgrad Program Biotechnol, Teresina, Brazil

Fundacao Oswaldo Cruz, Salvador, BA, Brazil

Univ Fed Piaui, Dept Pharm, Teresina, Brazil

Univ Fed Ceara, Fac Med, Dept Physiol & Pharmacol, Fortaleza, Ceara, Brazil

State Univ Sao Paulo, Inst Chem, Araraquara, Brazil

State Univ Sao Paulo, Ctr Med Nucl, Radioisotopes Res Lab, Sao Paulo, Brazil

State Univ Sao Paulo, Fac Med, Dept Radiol, Sao Paulo, Brazil

Univ Fed Ceara, Dept Clin Odontol, Fortaleza, Ceara, Brazil

Fundacao Oswaldo Cruz, Fortaleza, Ceara, Brazil

State Univ Sao Paulo, Inst Chem, Araraquara, Brazil

State Univ Sao Paulo, Ctr Med Nucl, Radioisotopes Res Lab, Sao Paulo, Brazil

State Univ Sao Paulo, Fac Med, Dept Radiol, Sao Paulo, Brazil

CNPq: 473167/2012-3

CNPq: 301976/2013-9

Document Type Journal article
Language English
facebook logo  linkedin logo  twitter logo 
mendeley logo

Related documents

No related documents